Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG301
- Development stage
- Phase 3
- Lead developer
- Hangzhou Sumgen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
SG301 is a novel humanized IgG1-kappa monoclonal antibody that targets the cell surface glycoprotein CD38. It binds to a unique epitope on CD38 distinct from other anti-CD38 antibodies such as daratumumab and isatuximab. The drug exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) activity compared to daratumumab and does not induce complement dependent cytotoxicity (CDC), which may reduce infusion-related reactions. In preclinical studies, SG301 demonstrated superior anti-tumor activity relative to daratumumab. It is being developed primarily for the treatment of multiple myeloma and systemic lupus erythematosus[1][2][3][4][5].
- Other names
- anti-CD38 monoclonal antibody SG301anti-CD-38 monoclonal antibody SG301anti-CD 38 monoclonal antibody SG301
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on SG301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SG301.